Loading
A phase 1/2 trial of Cevostamab, Tocilizumab in multiple myeloma, run by Hoffmann-La Roche, active and no longer recruiting.
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT05535244 by Hoffmann-La Roche, with 90 participants planned, started 2022-10-17 and due to reach its primary completion in 2027-02-26. Interventions recorded: Cevostamab, Tocilizumab. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Roche / Genentech, Multiple myeloma.
Shares Cevostamab, Tocilizumab, Roche / Genentech, Multiple myeloma.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Cevostamab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Tocilizumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Tocilizumab, Roche / Genentech.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/